Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D (UST1D)In type 1 diabetes (T1D), immune defense cells in the body attack and destroy insulin-producing beta cells leaving affected people with a lifelong need for daily insulin injections.Recruiting Principal Investigator Thomas G. ElliottBody Locations and Systems Diabetes - Type 1Area VancouverAge 18-35
Glucose Variability in Subclinical HypertrophyEvaluation of insulin absorption at sites affected by clinically apparent lipohypertrophy through short-term continuous glucose monitoring has shown inconsistent results and it is yet unknown how or if subclinical lipohypertrophy affects absorption.Recruiting Principal Investigator Graydon S. MeneillyBody Locations and Systems Diabetes - Type 1, Diabetes - Type 2Area VancouverAge 19 and above
Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02The purpose of this study is to evaluate the safety and efficacy of Relamorelin compared to placebo in patients with diabetic gastroparesis. Recruiting Principal Investigator Nazira ChaturBody Locations and Systems Diabetes - Type 1, Diabetes - Type 2Area VancouverAge 18 and above
Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time To determine the association between peripheral diabetic retinopathy lesions and the likelihood of diabetic retinopathy worsening or improving over time. Closed for Recruitment Principal Investigator David MaberleyBody Locations and Systems Diabetic Eye Problems, Diabetes - Type 1, Diabetes - Type 2Area VancouverAge 18 and above
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006…This trial is conducted globally. The aim of this trial is to assess clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes mellitus. Closed for Recruitment Principal Investigator David M. ThompsonBody Locations and Systems Diabetes - Type 1Area VancouverAge 18-45
